Aclarion, Inc. (Nasdaq: ACON, ACONW) has secured approximately $20 million to fully fund its pivotal CLARITY trial. This trial will evaluate Nociscan’s ability to improve surgical outcomes for patients with chronic low back pain by identifying the source of pain through MRI Spectroscopy and AI. The company aims to establish Nociscan as the standard for diagnosing low back pain.
This funding milestone is crucial because a successful CLARITY trial could lead to wider insurance coverage for Nociscan. This broader access would make the technology available to a larger patient population, potentially revolutionizing the diagnosis and treatment of chronic low back pain. Furthermore, positive trial results could solidify Nociscan’s position in the market, driving adoption among healthcare providers and establishing Aclarion as a leader in this space.
The CLARITY trial is a prospective, randomized, multicenter study involving 300 patients and led by Dr. Nicholas Theodore of Johns Hopkins. The study builds upon existing data suggesting Nociscan’s ability to guide more effective surgical interventions by accurately identifying painful discs. This precision could minimize unnecessary procedures and improve patient outcomes. The $20 million raised since the beginning of 2025 guarantees the trial’s completion.
Full funding for the CLARITY trial represents a significant step for Aclarion and its Nociscan technology. Positive results from the trial could transform the diagnosis and treatment of chronic low back pain, leading to better patient outcomes and significant market growth for Aclarion. The trial’s completion and subsequent data readout will be a critical inflection point for the company and the broader field of pain management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
